Related Experiment Videos
[Hypertrophy of the left ventricle--etiopathogenesis, clinical consequences and prognosis]
M A Ghanem Wisam1, J Murín, J Bulas
1I. interná klinika, Fakultná nemocnica a LF UK, Bratislava.
Insights
Reducing left ventricular hypertrophy through antihypertensive treatment benefits heart function in hypertensive patients. This intervention appears more favorable than harmful for the heart's pumping performance.
Area of Science:
- Cardiology
- Hypertension Research
- Cardiovascular Medicine
Context:
- Left ventricular hypertrophy (LVH) is a significant risk marker for cardiovascular morbidity and mortality in hypertensive individuals.
- LVH contributes to serious conditions such as sudden death, myocardial infarction, heart failure, stroke, and renal failure.
- Mechanisms linking LVH to cardiovascular risk are not fully elucidated, though pressure and volume overload are key factors.
Purpose:
- To explore the functional consequences of reducing ventricular hypertrophy.
- To clarify whether improvements in left ventricular function are due to mass reduction or decreased arterial pressure during antihypertensive treatment.
- To assess the overall impact of antihypertensive treatment-induced LVH reduction on cardiac function.
Summary:
- Left ventricular hypertrophy, often associated with hypertension, is linked to increased cardiovascular risks.
- While antihypertensive treatments can improve left ventricular function, the precise reasons (mass reduction vs. blood pressure decrease) require further differentiation.
- Studies suggest that reducing myocardial hypertrophy via specific antihypertensive therapies is generally beneficial for the heart's pump performance.
Impact:
- Provides insights into the benefits of managing left ventricular hypertrophy in hypertensive patients.
- Highlights the importance of considering LVH reduction as a therapeutic goal in hypertension management.
- Suggests that antihypertensive treatments aimed at reducing LVH can positively influence cardiac function and potentially reduce cardiovascular events.
Abstract:
The left ventricular hypertrophy is a risk marker of the cardiovascular morbidity and mortality in hypertensive patients--it contributes to sudden death, myocardial infarction, myocardial ischemia, heart failure, arrhythmias, left ventricular diastolic dysfunction, stroke and renal failure. The mechanisms by which the heart hypertrophy increases the risk of cardiovascular morbidity and mortality, however, is not completely clear yet. Pressure overload (resulting in the concentric hypertrophy) and volume overload (resulting in the eccentric hypertrophy) of the left ventricle play a significant role in the development of the hypertrophy of the left ventricle. Other risk factors, stimulating left ventricular hypertrophy, include growth factors, genetic predisposition, age, obesity, hyperinsulinemia and anemia. The hypertrophy of left ventricle most often occurs with hypertension, cardiomyopathy and aortic stenosis. Several clinical studies evaluated functional consequences of the reduction of the ventricular hypertrophy and found out that the function of the left ventricle to be improved in hypertensive patients who had undergone an effective and long-term antihypertensive treatment. However, these studies did not differentiate whether for the improvement in the function of left ventricle was the matter of the reduction of the left ventricular mass or whether it was because of the decrease of the arterial pressure during the period of anti-hypertensive treatment. On the basis of the literature studied we can emphasize that the reduction of myocardial hypertrophy resulting from a specific antihypertensive treatment appears to be more favourable than harmful for the heart's pump performance.